Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cryer, P. E.
Right arrow Articles by Sherwin, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cryer, P. E.
Right arrow Articles by Sherwin, R. S.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 38, Issue 9 1193-1199, Copyright © 1989 by American Diabetes Association


ARTICLES

Hypoglycemia in IDDM

PE Cryer, C Binder, GB Bolli, AD Cherrington, EA Gale, JE Gerich and RS Sherwin
Washington University School of Medicine, St. Louis, Missouri 63110.

Hypoglycemia causes substantial morbidity and some mortality in insulin-dependent diabetes mellitus (IDDM). It is often the limiting factor in attempts to achieve euglycemia. The prevention or correction of hypoglycemia normally involves both dissipation of insulin and activation of glucose counterregulatory systems. Among the latter, glucagon plays a primary role initially, whereas epinephrine is not critical, although it becomes critical when glucagon is deficient. Growth hormone and cortisol play demonstrable roles in recovery from prolonged hypoglycemia. Glucose autoregulation may be involved in defense against severe hypoglycemia. With respect to pathophysiology, counterregulatory systems are involved in at least five clinical glucoregulatory syndromes. Defective glucose counterregulation is associated with, and best attributed to, combined deficiencies of the glucagon and epinephrine responses to plasma glucose decrements. Almost assuredly in concert with hypoglycemia unawareness, it results in a markedly increased frequency of severe hypoglycemia, at least during intensive therapy of IDDM. Defined as a night to morning increase in plasma glucose concentration, the dawn phenomenon is thought to result from dissipation of insulin plus the effects of nocturnal growth hormone secretion. Despite a sound rationale, the clinical relevance of the Somogyi phenomenon has been recently questioned. The clinical impression of altered glycemic thresholds for symptoms, i.e., patients with poorly controlled IDDM suffer symptoms of hypoglycemia at relatively high plasma glucose levels, whereas those with very well-controlled IDDM often tolerate subnormal glucose levels, has received experimental support. Clearly, hypoglycemia in IDDM is a problem that needs to be solved. Numerous issues need to be addressed through both basic and clinical research.(ABSTRACT TRUNCATED AT 250 WORDS)
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Diabetes CareHome page
J. Geddes, R. J. Wright, N. N. Zammitt, I. J. Deary, and B. M. Frier
An Evaluation of Methods of Assessing Impaired Awareness of Hypoglycemia in Type 1 Diabetes
Diabetes Care, July 1, 2007; 30(7): 1868 - 1870.
[Full Text] [PDF]


Home page
DiabetesHome page
R. A. Heptulla, L. M. Rodriguez, L. Bomgaars, and M. W. Haymond
The Role of Amylin and Glucagon in the Dampening of Glycemic Excursions in Children With Type 1 Diabetes
Diabetes, April 1, 2005; 54(4): 1100 - 1107.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
F. Whitehouse, D. F. Kruger, M. Fineman, L. Shen, J. A. Ruggles, D. G. Maggs, C. Weyer, and O. G. Kolterman
A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes
Diabetes Care, April 1, 2002; 25(4): 724 - 730.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
C. Allen, T. LeCaire, M. Palta, K. Daniels, M. Meredith, and D. J. D'Alessio
Risk Factors for Frequent and Severe Hypoglycemia in Type 1 Diabetes
Diabetes Care, November 1, 2001; 24(11): 1878 - 1881.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. G. Bischof, M. Krssak, M. Krebs, E. Bernroider, H. Stingl, W. Waldhäusl, and M. Roden
Effects of Short-Term Improvement of Insulin Treatment and Glycemia on Hepatic Glycogen Metabolism in Type 1 Diabetes
Diabetes, February 1, 2001; 50(2): 392 - 398.
[Abstract] [Full Text]


Home page
Postgrad. Med. J.Home page
M Güven, F Bayram, K Güven, and F Kelestimur
Evaluation of patients admitted with hypoglycaemia to a teaching hospital in Central Anatolia
Postgrad. Med. J., March 1, 2000; 76(893): 150 - 152.
[Abstract] [Full Text]


Home page
JAMAHome page
M. A. Testa and D. C. Simonson
Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled, Double-Blind Trial
JAMA, November 4, 1998; 280(17): 1490 - 1496.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1989 by the American Diabetes Association.